DOCSLIB.ORG

Psychopharmacology Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Psychopharmacology Update FUQUA CENTER FOR LATE-LIFE DEPRESSION PSYCHOPHARMACOLOGY UPDATE Eve H. Byrd, MSN, MPH, FNP.BC, Psych CNS Fuqua Center for Late-Life Depression Emory University Most Common Disorders in Older Adults FUQUA CENTER FOR LATE-LIFE DEPRESSION In order of prevalence: Anxiety Severe cognitive impairment Mood disorders Am Assoc of Geriatric Psychiatry, 2011 Growing number of older adults with Psychotic Disorders Epidemiology – Depressive Syndromes FUQUA CENTER FOR LATE-LIFE DEPRESSION Community dwelling older adults 1%-4% Major Depressive Disorder 35% depressive symptoms Long Term Care older adults 10- 15% depressive syndromes Blazer DG. Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci 2003; 58(3): 249–65. Hybels CF, Blazer DG. Epidemiology of late‐life mental disorders. Clin Geriatr Med 2003; 19(4): 663–96, v. Impact FUQUA CENTER FOR LATE-LIFE DEPRESSION Increased health care costs Increased service utilization 5.3 office visits for vs. 2.9/ per year without depression Less compliance with medical treatment Hospital readmissions Katon WJ, Lin E, Russo J, Unutzer J. Increased medical costs of a population‐based sample of depressed elderly patients. Arch Gen Psychiatry. 2003 Sep;60(9):897‐903; Alexopoulos GS. Depression in the elderly. Lancet 2005; 365(9475): 1961–70. Medical Evaluation FUQUA CENTER FOR LATE-LIFE DEPRESSION Medical History Psychosocial History (drug, etoh, marriages, work hx) Family Medical/ Psychiatric History Labs (CBC, Chem 7, B12 and Folate, TSH, vitamin D) CT scan (when there are concerns regarding memory or psychosis) Depressive Disorders DSM V Major Depressive Disorder FUQUA CENTER FOR LATE-LIFE DEPRESSION At least one of the two, (1) depressed mood or (2) loss of interest or pleasure 5+ symptoms, 2-week period, represent a change from previous functioning Major Depressive Disorder FUQUA CENTER FOR LATE-LIFE DEPRESSION Weight loss when not dieting or weight gain Insomnia or hypersomnia nearly Psychomotor agitation or retardation Fatigue or loss of energy Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) Diminished ability to think or concentrate, or indecisiveness Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide. Others FUQUA CENTER FOR LATE-LIFE DEPRESSION Unspecified Depressive Disorder Substance/Medication- Induced Depressive Disorder Depressive Disorder Due to Another Medical Condition Geriatric Depression FUQUA CENTER FOR LATE-LIFE DEPRESSION Cognitive changes Somatic symptoms Fatigue Loss of interest Depression without sadness Kamara TS, Whyte EM, Mulsant BH et al. Does major depressive disorder with somatic delusions constitute a distinct subtype of major depressive disorder with psychotic features? J Affect Disord 2009; Gallo JJ, Rabins PV, Lyketsos LG, Tien AY, Anthony JC. Depression without sadness: functional outcomes of nondysphoric depression in later life. J Am Geriatr Soc. 1997;45:570-578; Sneed JR, Culang ME, Keilp JG, et al. Antidepressant medication and executive dysfunction: a deleterious interaction in late-life depression. Am J Geriatr Psychiatry 2010; 18:128–135. Depression and Dementia FUQUA CENTER FOR LATE-LIFE DEPRESSION Over 50% of patients with dementia have depressive symptoms 20% meet major depressive criteria Brown EL, Raue P, Halpert KD, Adams S, Titler MG. Detection of depression in older adults with dementia. J Gerontol Nurs 2009; 35(2): 11–15. Symptoms of Depression vs. Dementia FUQUA CENTER FOR LATE-LIFE DEPRESSION Depression: Impairment in attention Psychomotor slowing Slowed speed of information processing Impaired executive functioning Dementia: Global cognitive impairment Dementia vs. Depressive Disorder FUQUA CENTER FOR LATE-LIFE DEPRESSION Dementia Screening and/or neuropsychological test Depressed - show poor effort, results inconsistent over time Dementia - cover deficits with confabulations Treatment Mild Depression FUQUA CENTER FOR Expert Consensus Guidelines LATE-LIFE DEPRESSION Preferred Treatment Alternate Treatment Antidepressant Antidepressant alone medication and or psychotherapy psychotherapy alone SSRI, Venlafaxine XR Bupropion, Mirtazapine Adapted from Alexopolus et al (2001)A postgraduate medicine special report Severe Depression FUQUA CENTER FOR Expert Consensus Guidelines LATE-LIFE DEPRESSION Preferred Treatment Alternate Treatment Antidepressant Electroconvulsive medication and Therapy psychotherapy OR Tricyclic antidepressant antidepressants, medication alone Mirtazapine, SSRI, Bupropion Venlafaxine XR (SNRI) Adapted from Alexopolus et al, Pharmacotherapy FUQUA CENTER FOR LATE-LIFE DEPRESSION st 1 choice - Selective serotonin reuptake inhibitors (SSRIs) nd 2 choice - Serotonin-Norepinephrine reuptake inhibitors (SNRIs) Roose S, Schatzberg AF. The efficacy of antidepressants in the treatment of late‐life depression. J Clin Psychopharmacol 2005; 25:S1–7 Pharmacotherapy FUQUA CENTER FOR LATE-LIFE DEPRESSION Selective Serotonin Reuptake Inhibitors Fluoxetine (Prozac) Sertraline (Zoloft) Paroxetine (Paxil) Citalopram (Celexa) Escitalopram (Lexapro) Fluvoxamine (Luvox) SSRIs Side Effects FUQUA CENTER FOR LATE-LIFE DEPRESSION Headache GI side effects Hyponatremia Excessive activation Sleep disturbance Tremor Sexual dysfunction QT prolongation (Citalopram 20mg or less) Pharmacokinetics FUQUA CENTER FOR LATE-LIFE DEPRESSION Inhibition of CP450 Strongest - Fluoxetine (Prozac), flovoxamine, nefazodone Caution SSRIs and WARFARIN Inhibition of P450 cytochromes FUQUA CENTER FOR LATE-LIFE DEPRESSION Drug Name CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4 CYP2B6 Citalopram+00+00 Escitalopram000+00 Fluoxetine + ++ +/++ +++ + + Fluvoxamine +++ ++ +++ + + + Paroxetine + + + +++ + +++ Sertraline+++/+++++ Pharmacotherapy FUQUA CENTER FOR LATE-LIFE DEPRESSION Serotonin and Norepinephrine Reuptake Inhibitors Venlafaxine (Effexor, Effexor XR) Duloxetine (Cymbalta) Desvenlafaxine (Pristiq) Milnacipran (Ixel, Savella) Levomilnacipran (Fetzima) Tofenacin (Elamol, Tofacine) SNRI Side Effects FUQUA CENTER FOR LATE-LIFE DEPRESSION Most common: loss of appetite, weight loss, and sleep disturbance. Possible: drowsiness, dizziness, fatigue, headache, increase in suicidal thoughts, nausea/vomiting, sexual dysfunction (less than in SSRIs), and urinary retention. SNRI Side Effects FUQUA CENTER FOR LATE-LIFE DEPRESSION Increased Norepinephrine: anxiety, mildly elevated pulse, and elevated blood pressure – usually dose related Cymbalta – Monitor liver function tests and creatinine Serotonin and Psychiatric Symptoms FUQUA CENTER FOR LATE-LIFE DEPRESSION Mood Anxiety: OCD, GAD, PTSD, Social Phobia & Panic Disorder Impulsivity Aggression Eating Disorders: Bulimia, Anorexia Pharmacotherapy FUQUA CENTER FOR LATE-LIFE DEPRESSION Others Mirtazapine (Remeron) – Noradrenergic and specific serotonergic Bupropion (Wellbutrin) (SR/XL) – Norepinephrine Reuptake Inhibitor and non-competitive antagonist of multiple neuronal n ACH receptors Mirtazapine (Remeron) FUQUA CENTER FOR LATE-LIFE DEPRESSION Helpful when do not tolerate SSRIs Sedating at low dosage Stimulates appetite Minimal warfarin interaction Could exacerbate REM sleep behavior in PD Neutropenia, agranulocytosis Onofrj M, Luciano AL, Thomas A, Iacono D, D’Andreamatteo G. Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology 2003;60:113–5. Bupropion FUQUA CENTER FOR LATE-LIFE DEPRESSION CYP2D6 inhibitor ↑ paroxetine, sertraline, fluoxetine, diazepam ↑ bupropion blood levels CYP2B6 inducers, such as carbamazepine, clotrimazole, rifampicin, ritonavir, St John's Wort, phenobarbital, phenytoin and others ↓ bupropion Bupropion lowers the threshold for epileptic seizures Bupropion FUQUA CENTER FOR LATE-LIFE DEPRESSION No sexual dysfunction Smoking cessation Activating (will cause sleep disturbance if given late in day) Asthenia Alopecia Pharmacotherapy FUQUA CENTER FOR Older Medications LATE-LIFE DEPRESSION Tricyclics MAOIs Nortriptyline (Pamelor) Isocarboxazid (Marplan) Amitriptyline (Elavil) Phenalzine (Nardil) Desipramine (Norpramin) Tranylcypromine (Parnate) Imipramine (Tofranil) Selegiline (EMSAME) Doxepin (Adapin, patch Sinequan) etc Clomipramine (Anafranil) etc Dosing guidelines FUQUA CENTER FOR LATE-LIFE DEPRESSION Muslant, et al (2001) Pharmacologic treatment of depression in older adults: PROSPECT algorithm. International Jrnl of Geriatric Psychiatry, 16, 582-589 Depression with Psychosis FUQUA CENTER FOR LATE-LIFE DEPRESSION Depression with psychotic symptoms is common among elderly patients. Somatic delusions, nihilism, persecution and jealousy are common psychotic features. Treatment should include the association of antidepressants and antipsychotics to improve treatment efficacy. Meyers BS, Flint AJ, Rothschild AJ, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry 2009; 66:838–847. Adjunctive treatments FUQUA CENTER FOR LATE-LIFE DEPRESSION Atypical antipsychotics Others Aripiprazole (Abilify) Buspirone (Buspar) Lurasidone (Latuda) Lithium (Eskalith, Olanzapine (Zyprexa) Lithobid) Quetiapine (Seroquel) Thyroid hormone Risperdidone (Risperdal) Ziprasidone (Geodon) Electroconvulsive Therapy (ECT) FUQUA CENTER FOR LATE-LIFE DEPRESSION 80% response
Load more

Recommended publications
  • Depression in the Older Adults
    Depression in the Older Adults Summary Major depressive disorder (MDD) is the leading cause of disability according to the World Health Organization. Common clinical conditions and previous research has shown that the worldwide prevalence is approximately 15% in community-dwelling individuals. Significant depressive symptoms are present in nearly 15% of older adults living in the community, especially in those older adults who have chronic illness and pain. Depression in later life is associated with greater risk of suicide, ischemic heart disease, heart failure, osteoporosis and poor cognitive and social functioning. Physiologically it is associated with changes such as hypercortisolemia, visceral adiposity, and higher risk of hypertension and diabetes mellitus. Key Points Depression in the older adult • amplifies disability/pain • lessens quality of life and increases mortality • results in increasing office and emergency department visits • results in more prescription and OTC medication use • leads to increased alcohol and drug use • increases length of hospital stay Eighty percent (80%) of mental health treatment for depressed older adults is delivered in the primary care setting. It is estimated that 10-15 percent of older adults with intact cognitive functioning have depression. Health care providers should screen all geriatric patients for depression. Greater than 50% of nursing home residents are depressed. Dementia syndrome of depression is defined as a cognitive impairment present in an elderly patient with major depression
    [Show full text]
  • Old Age Bipolar Disorder—Epidemiology, Aetiology and Treatment
    medicina Review Old Age Bipolar Disorder—Epidemiology, Aetiology and Treatment Ivan Arnold 1, Julia Dehning 2,*, Anna Grunze 3 and Armand Hausmann 4 1 Helios Klinik Berlin-Buch, 13125 Berlin, Germany; [email protected] 2 Department of Psychiatry, Psychotherapy and Psychosomatics, Medical University Innsbruck, 6020 Innsbruck, Austria 3 Psychiatrisches Zentrum Nordbaden, 69168 Wiesloch, Germany; [email protected] 4 Private Practice, Wilhelm-Greil-Straße 5, 6020 Innsbruck, Austria; [email protected] * Correspondence: [email protected]; Tel.: +43-512-504-83802 Abstract: Data regarding older age bipolar disorder (OABD) are sparse. Two major groups are classified as patients with first occurrence of mania in old age, the so called “late onset” patients (LOBD), and the elder patients with a long-standing clinical history, the so called “early onset” patients (EOBD). The aim of the present literature review is to provide more information on specific issues concerning OABD, such as epidemiology, aetiology and treatments outcomes. We conducted a Medline literature search from 1970–2021 using the MeSH terms “bipolar disorder” and “aged” or “geriatric” or “elderly”. The additional literature was retrieved by examining cross references and by a hand search in textbooks. With sparse data on the treatment of OABD, current guidelines concluded that first-line treatment of OABD should be similar to that for working-age bipolar disorder, with specific attention to side effects, somatic comorbidities and specific risks of OABD. With constant monitoring and awareness of the possible toxic drug interactions, lithium is a safe drug for OABD patients, both in mania and maintenance. Lamotrigine and lurasidone could be considered in bipolar Citation: Arnold, I.; Dehning, J.; depression.
    [Show full text]
  • Knowledge of Late-Life Depression Among Staff in Long-Term Care Facilities in Both Urban and Rural Montana Using Two Instruments
    KNOWLEDGE OF LATE-LIFE DEPRESSION AMONG STAFF IN LONG-TERM CARE FACILITIES by Julie Marie Pullen A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Nursing MONTANA STATE UNIVERSITY Bozeman, Montana June, 2004 © COPYRIGHT by Julie Marie Pullen 2004 All Rights Reserved ii APPROVAL of a thesis submitted by Julie Marie Pullen This thesis has been read by each member of the thesis committee and has been found to be satisfactory regarding content, English usage, format, citations, bibliographic style, and consistency, and is ready for submission to the College of Graduate Studies. Dr. Vonna Branam, Chairperson Approved for the College of Nursing Dr. Jean Ballantyne Approved for the College of Graduate Studies Dr. Bruce McLeod iii STATEMENT OF PERMISSION TO USE In presenting this thesis in partial fulfillment of the requirements for a master’s degree Montana State University, I agree that the Library shall make it available to borrowers under rules of the Library. If I have indicated my intention to copyright this thesis by including a copyright notice page, copying is allowable only for scholarly purposes, consistent with “fair use” as prescribed in the U.S. Copyright Law. Requests for permission for extended quotation from our reproduction of this thesis in whole or in part may be granted only by the copyright holder. Julie Marie Pullen June 1, 2004 iv This thesis is dedicated to my husband, Rick Pullen, a gifted physician who has spent many years healing those who suffer from depression and other mental illnesses. v The author wishes to thank committee members who guided me through this educational journey: Dr.
    [Show full text]
  • Current P SYCHIATRY
    Current p SYCHIATRY When and how to use SSRIs to treat late-life depression When antidepressants are indicated for older patients, our goal is to achieve the maximum therapeutic effect with the lowest effective dosage and minimal side effects espite its impact on individuals and public health, depression in older persons is inadequately D diagnosed and treated. Even when depression is diagnosed, only one-third of persons older than 65 receive treatment.1 Reasons for this include: • lack of physician awareness that depression presents John W. Kasckow, MD, PhD, and differently in older than in younger adults J. Jeffrey Mulchahey, PhD • patient denial of depressive symptoms Associate professors • patients’ and physicians’ mistaken belief that feeling Jim Herman, PhD depressed is a normal part of aging. Professor The good news is that when geriatric depression is Muhammed Aslam, MD recognized, it usually responds favorably to treatment, Assistant professor although aggressive intervention may be required.2 In this Mya Sabia, MD article, we describe our approach to diagnosis and discuss use Resident in geropsychiatry of selective serotonin reuptake inhibitors (SSRIs) as first-line Department of Psychiatry antidepressants for older patients. University of Cincinnati College of Medicine Cincinnati, OH Late-life depression risk factors Somaia Mohamed, MD, PhD Director, Division of General Psychiatry Depression is common in older persons, especially in those Cincinnati VA Medical Center who have experienced psychosocial or medical losses, includ- VOL. 2, NO. 1 / JANUARY 2003 43 Late-life depression Box • medication side effects CASE REPORT: • bipolar disorder, which may require the use of a DEPRESSED, AT RISK FOR SUICIDE mood-stabilizing agent to prevent manic symp- toms.3 72-year-old man presents with trouble concentrat- History.
    [Show full text]
  • Institutional Review Board
    New York State Psychiatric Institute Institutional Review Board February 08, 2019 To: Dr. Bret Rutherford From: Dr. Edward Nunes, IRB Co-Chair Dr. Agnes Whitaker, IRB Co-Chair Subject: Approval Notice: Continuation Expedited per 45CFR46.110(b)(1)(f)(8c) Your protocol # 7270 entitled: A STUDY OF L-DOPA FOR DEPRESSION AND SLOWING IN OLDER ADULTS Protocol version date 02/08/2019 has been approved by the New York State Psychiatric Institute - Columbia University Department of Psychiatry Institutional Review Board from March 07, 2019 to March 06, 2020. Consent requirements: √ Not applicable: Data Analysis Only 45CFR46.116 (d) waiver of consent Signature by the person(s) obtaining consent is required to document the consent process Documentation of an independent assessment of the participant’s capacity to consent is also required. Approved for recruitment of subjects who lack capacity to consent: No Yes Field Monitoring Requirements: Routine Special: ___________________ Only copies of consent documents that are currently approved by the IRB may be used to obtain consent for participation in this study. A progress report and application for continuing review is required 2 months prior to the expiration date of IRB approval. Changes to this research may not be initiated without the review and approval of the IRB except when necessary to eliminate immediate hazards to participants. All serious and/or unanticipated problems or events involving risks to subjects or others must be reported immediately to the IRB. Please refer to the PI-IRB website at http://irb.nyspi.org for Adverse Event Reporting Procedures and additional reporting requirements. Cc: RFMH Business Office (NIMH R61 MH110029; CU Subcontract) EN/AHW/alw Signed copy on file at IRB v.
    [Show full text]
  • Substance Abuse Among Older Adults: Treatment Improvement Protocol (TIP) Series 26
    TIP 26: Substance Abuse Among Older Adults: Treatment Improvement Protocol (TIP) Series 26 A48302 Frederic C. Blow, Ph.D. Consensus Panel Chair U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment Rockwall II, 5600 Fishers Lane Rockville, MD 20857 Disclaimer This publication is part of the Substance Abuse Prevention and Treatment Block Grant technical assistance program. All material appearing in this volume except that taken directly from copyrighted sources is in the public domain and may be reproduced or copied without permission from the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Substance Abuse Treatment (CSAT) or the authors. Citation of the source is appreciated. This publication was written under contract number ADM 270-95-0013. Sandra Clunies, M.S., I.C.A.D.C., served as the CSAT Government project officer. Writers were Paddy Cook, Carolyn Davis, Deborah L. Howard, Phyllis Kimbrough, Anne Nelson, Michelle Paul, Deborah Shuman, Margaret K. Brooks, Esq., Mary Lou Dogoloff, Virginia Vitzthum, and Elizabeth Hayes. Special thanks go to Roland M. Atkinson, M.D.; David Oslin, M.D.; Edith Gomberg, Ph.D.; Kristen Lawton Barry, Ph.D.; Richard E. Finlayson, M.D.; Mary Smolenski, Ed.D., C.R.N.P.; MaryLou Leonard; Annie Thornton; Jack Rhode; Cecil Gross; Niyati Pandya; Mark A. Meschter; and Wendy Carter for their considerable contributions to this document. The opinions expressed herein are the views of the Consensus Panel members and do not reflect the official position of CSAT, SAMHSA, or the U.S.
    [Show full text]
  • Psychiatric Issues
    13 Psychiatric Issues MONICA MATHYS and MYRA T. BELGERI Learning Objectives 1. Recognize the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria for major depressive disorder, anxiety disorders, and features commonly observed in late-life depression and anxiety. 2. Recommend an appropriate treatment plan for a geriatric patient suffering from depression and/or anxiety. 3. Recognize the changes in sleep that occur with normal aging and the impact of insomnia on an elderly patient’s health and quality of life. 4. Recommend appropriate therapy for insomnia based on published evidence in the elderly patient. 5. Describe the limitations of the DSM-5 criteria when used to diagnose elderly patients with substance-use disorders. 6. List the alcohol drinking limits for geriatric patients and discuss the reasons why guidelines suggest lower limits compared to younger adults. 7. Recommend an appropriate treatment plan for alcohol withdrawal and long-term abstinence for a geriatric patient. Key Terms and Definitions CLINICAL GLOBAL IMPRESSION OF IMPROVEMENT (CGI-I): Seven-point scale that measures how much a patient’s symptoms have improved or worsened compared to baseline. COGNITIVE BEHAVIORAL THERAPY: Therapy to help patients correct negative thoughts associated with depression and to cope with anxiety disorders. The therapy includes breathing retraining, muscle relaxation, cognitive restructuring to focus on the consistent worrying, and graded exposure so the patient can learn how to cope in stressful/phobic situations. 378 | Fundamentals of Geriatric Pharmacotherapy EARLY-ONSET ALCOHOLISM/ABUSE/DEPENDENCE: Alcohol abuse/dependence in which onset occurs before the age of 50. HAMILTON RATING SCALE FOR ANXIETY (HRSA): Fourteen-item assessment tool appropriate for measuring symptom severity and treatment response for generalized anxiety disorder (GAD).
    [Show full text]
  • California Behavioral Health Planning Council
    California Behavioral Health Planning Council Advocacy Evaluation Inclusion Older Adults Experiencing First Episode Psychosis and Late Onset of Serious Mental Illness June 2018 The California Behavioral Health Planning Council (Council) is under federal and state mandate to advocate on behalf of adults with severe mental illness and children with severe emotional disturbance and their families. The Council is also statutorily required to advise the Legislature on behavioral health issues, policies and priorities in California. The Council advocates for an accountable system of seamless, responsive services that are strength-based, consumer and family member driven, recovery oriented, culturally and linguistically responsive and cost effective. Council recommendations promote cross-system collaboration to address the issues of access and effective treatment for the recovery, resiliency and wellness of Californians living with severe mental illness. 2 | Page Introduction: The California Behavioral Health Planning Council (CBHPC) serves as a federal and state mandated advisory body to the California Department of Health Care Services and Legislature on policies and priorities for the behavioral health system and to provide recommendations for behavioral health services across the life span. In response to recent legislative activity around First Episode Psychosis (FEP) to amend current law for the use of Prevention and Early Intervention funding, the Council explored available literature and data regarding late onset of serious mental illnesses such as Bipolar and Depression. While early intervention for transition age youth (TAY) has become increasingly vital to help prevent the full-onset of chronic serious mental illness (SMI) and to improve long-term outcomes - there is another segment of the population that experiences FEP later in life.
    [Show full text]
  • The Association of Late-Life Depression, Cognitive Functioning, and Sleep Disorder in Aging
    The University of Maine DigitalCommons@UMaine Electronic Theses and Dissertations Fogler Library Summer 8-7-2019 The Association of Late-Life Depression, Cognitive Functioning, and Sleep Disorder in Aging Jessica B. Aronis University of Maine, [email protected] Follow this and additional works at: https://digitalcommons.library.umaine.edu/etd Part of the Developmental Neuroscience Commons Recommended Citation Aronis, Jessica B., "The Association of Late-Life Depression, Cognitive Functioning, and Sleep Disorder in Aging" (2019). Electronic Theses and Dissertations. 3115. https://digitalcommons.library.umaine.edu/etd/3115 This Open-Access Thesis is brought to you for free and open access by DigitalCommons@UMaine. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of DigitalCommons@UMaine. For more information, please contact [email protected]. THE ASSOCIATION OF LATE-LIFE DEPRESSION, COGNITIVE FUNCTIONING, AND SLEEP DISORDER IN AGING By Jessica Aronis B.A. Colby College, 2016 A THESIS Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Arts (in Psychology) The Graduate School University of Maine August 2019 Advisory Committee: Marie J. Hayes, Professor of Psychology, Advisor Ali Abedi, Professor of Electrical & Computer Engineering Fayeza Ahmed, Assistant Professor of Psychology Clifford Singer, Chief of Geriatric Mental Health and Neuropsychology Services © 2019 Jessica Aronis All Rights Reserved ii THE ASSOCIATION OF LATE-LIFE DEPRESSION, COGNITIVE FUNCTIONING, AND SLEEP DISORDER IN AGING By Jessica Aronis Thesis Advisor: Dr. Marie J. Hayes An Abstract of Thesis Presented In Partial Fulfillment of the Requirements for the Degree of Master of Arts (in Psychology) August 2019 The continuing growth in the demographic of aging individuals in the United States creates concern for diseases of aging that are chronic, notably unipolar depressive disorders.
    [Show full text]
  • Issue Brief 4: Preventing Suicide in Older Adults Introduction and Overview
    OLDER AMERICANS BEHAVIORAL HEALTH Issue Brief 4: Preventing Suicide in Older Adults Introduction and Overview The Substance Abuse and Mental Health Services Administration (SAMHSA) and Administration on Aging (AoA) recognize the value of strong partnerships for addressing behavioral health issues among older adults. This Issue Brief is part of a larger collaboration between SAMHSA and AoA to support the planning and coordination of aging and behavioral health services for older adults in states and communities. Through this collaboration, SAMHSA and AoA are providing technical expertise and tools, particularly in the areas of anxiety, depression, and alcohol and prescription drug use and misuse among older adults, and are partnering to get these resources into the hands of aging and behavioral health professionals. This Issue Brief is intended to help health care and social service organizations develop strategies to prevent suicide in older adults by providing: • Information on the prevalence, risk factors, and lethality of suicide attempts in older adults; • Recommendations on universal, selective, and indicated prevention strategies; • Guidance for health and human service professionals on how to assess suicide risk and take appropriate actions to keep an older adult safe; and • Suggestions and Resources to help aging services, behavioral health, and primary care providers develop and adopt effective suicide Suicide in Older Adults prevention programs. An estimated 8,618 older Americans (ages 60+) died from suicide • Social isolation, in 2010. Although the rate of suicide for women typically declines • Family discord or losses (e.g., recent death of a loved one), in older age, it increases with age among men. Older men die by • Inflexible personality or marked difficulty adapting to change, suicide at a rate that is more than seven times higher than that of • Access to lethal means (e.g., firearms), older women.
    [Show full text]
  • How to Adapt Cognitive-Behavioral Therapy for Older Adults
    Web audio at CurrentPsychiatry.com Dr. Chand: Key points on providing CBT to older patients How to adapt cognitive-behavioral therapy for older adults To improve efficacy, focus on losses, transitions, and changes in cognition ome older patients with depression, anxiety, or insom- nia may be reluctant to turn to pharmacotherapy and Smay prefer psychotherapeutic treatments.1 Evidence has established cognitive-behavioral therapy (CBT) as an effective intervention for several psychiatric disorders and CBT should be considered when treating geriatric patients (Table 1).2 Research evaluating the efficacy of CBT for depression in older adults was first published in the early 1980s. Since then, research and application of CBT with older adults has expanded to include other psychiatric disorders and re- searchers have suggested changes to increase the efficacy of CBT for these patients. This article provides: © JOHN LUND/MARC ROMANELLI/BLEND IMAGES/CORBIS • an overview of CBT’s efficacy for older adults with de- Suma P. Chand, PhD pression, anxiety, and insomnia Associate Professor • modifications to employ when providing CBT to older George T. Grossberg, MD patients. Samuel W. Fordyce Professor Director, Geriatric Psychiatry • • • • The cognitive model of CBT Department of Neurology and Psychiatry In the 1970s, Aaron T. Beck, MD, developed CBT while Saint Louis University School of Medicine working with depressed patients. Beck’s patients reported St. Louis, MO thoughts characterized by inaccuracies and distortions in association with their depressed mood. He found these thoughts could be brought to the patient’s conscious atten- tion and modified to improve the patient’s depression. This finding led to the development of CBT.
    [Show full text]
  • Detecting Late-Life Depression in Alzheimer's Disease Through
    Detecting late-life depression in Alzheimer’s disease through analysis of speech and language Kathleen C. Fraser1 and Frank Rudzicz2,1 and Graeme Hirst1 1Department of Computer Science, University of Toronto, Toronto, Canada 2Toronto Rehabilitation Institute-UHN, Toronto, Canada kfraser,frank,gh @cs.toronto.edu { } Abstract It is also important to detect when someone has both AD and depression, as this serious situation can Alzheimer’s disease (AD) and depression lead to more rapid cognitive decline, earlier place- share a number of symptoms, and commonly ment in a nursing home, increased risk of depression occur together. Being able to differentiate be- in the patient’s caregivers, and increased mortality tween these two conditions is critical, as de- (Thorpe, 2009; Lee and Lyketsos, 2003). pression is generally treatable. We use linguis- Separate bodies of work have reported the util- tic analysis and machine learning to determine whether automated screening algorithms for ity of spontaneous speech analysis in distinguish- AD are affected by depression, and to detect ing participants with depression from healthy con- when individuals diagnosed with AD are also trols, and in distinguishing participants with demen- showing signs of depression. In thefirst case, tia from healthy controls. Here we consider whether wefind that our automated AD screening pro- such analyses can be applied to the problem of de- cedure does not show false positives for indi- tecting depression in Alzheimer’s disease (AD). In viduals who have depression but are otherwise particular, we explore two questions: (1) In previous healthy. In the second case, we have moderate success in detecting signs of depression in AD work on detecting AD from speech (elicited through (accuracy = 0.658), but we are not able to draw a picture description task), are cognitively healthy a strong conclusion about the features that are people with depression being misclassified as hav- most informative to the classification.
    [Show full text]